Compass Ion Advisors LLC Sells 1,907 Shares of Pfizer Inc. $PFE

Compass Ion Advisors LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.0% in the second quarter, HoldingsChannel.com reports. The fund owned 21,924 shares of the biopharmaceutical company’s stock after selling 1,907 shares during the quarter. Compass Ion Advisors LLC’s holdings in Pfizer were worth $531,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Vident Advisory LLC bought a new stake in shares of Pfizer during the 4th quarter worth $248,000. Vise Technologies Inc. lifted its holdings in shares of Pfizer by 11.4% during the 4th quarter. Vise Technologies Inc. now owns 75,848 shares of the biopharmaceutical company’s stock worth $2,012,000 after acquiring an additional 7,759 shares during the last quarter. Finally, Fourth Dimension Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth $74,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Bank of America lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.12.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.03 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company’s 50-day moving average is $24.63 and its 200 day moving average is $24.21. The stock has a market capitalization of $136.62 billion, a P/E ratio of 12.78, a P/E/G ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.